Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. Earnings Recaps

IMDX 1 recap
Q3 2025 Nov 11, 2025

Insight Molecular Diagnostics demonstrated significant progress in their Q3 2025 performance, highlighting advancements in their GraftAssure DX assay and preparing for an anticipated strong market introduction in 2026.

Key takeaways
  • Successfully optimized GraftAssure DX’s test workflow from two steps to one, enhancing turnaround time and ease of use for transplant centers.
  • Positive feedback and data from pilot studies at multiple sites indicate high confidence in assay performance ahead of the upcoming FDA submission.
  • A growing interest in in-house testing from transplant centers drives demand, supported by a new registry program aimed at collecting real-world data on the assay’s performance.
  • Statistical equivalence demonstrated against legacy tests reinforces GraftAssure’s competitive position, enabling easier transitions for clinicians.
  • First reports using the anticipated Centimeters score are expected in 2026, with early access for registry participants, fostering early adoption.
Full recap